These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38923272)

  • 1. Efficacy and safety of once-weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus-A systematic review and meta-analysis of randomized controlled trials.
    Kommu S; Berg RL
    Obes Rev; 2024 Jun; ():e13792. PubMed ID: 38923272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
    Rubino DM; Greenway FL; Khalid U; O'Neil PM; Rosenstock J; Sørrig R; Wadden TA; Wizert A; Garvey WT;
    JAMA; 2022 Jan; 327(2):138-150. PubMed ID: 35015037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.
    Rubino D; Abrahamsson N; Davies M; Hesse D; Greenway FL; Jensen C; Lingvay I; Mosenzon O; Rosenstock J; Rubio MA; Rudofsky G; Tadayon S; Wadden TA; Dicker D;
    JAMA; 2021 Apr; 325(14):1414-1425. PubMed ID: 33755728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta-analysis including the 2-year STEP 5 trial.
    Qin W; Yang J; Deng C; Ruan Q; Duan K
    Diabetes Obes Metab; 2024 Mar; 26(3):911-923. PubMed ID: 38016699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis.
    Zhong P; Zeng H; Huang M; Fu W; Chen Z
    Endocrine; 2022 Mar; 75(3):718-724. PubMed ID: 34981419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once-Weekly Semaglutide in Adults with Overweight or Obesity.
    Wilding JPH; Batterham RL; Calanna S; Davies M; Van Gaal LF; Lingvay I; McGowan BM; Rosenstock J; Tran MTD; Wadden TA; Wharton S; Yokote K; Zeuthen N; Kushner RF;
    N Engl J Med; 2021 Mar; 384(11):989-1002. PubMed ID: 33567185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide in Overweight or Obese Adults: A Systematic Review with Meta-Analysis.
    Dorneles G; Algeri E; Lauterbach G; Pereira M; Fernandes B
    Exp Clin Endocrinol Diabetes; 2024 Jun; 132(6):316-327. PubMed ID: 38599612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial.
    Kadowaki T; Isendahl J; Khalid U; Lee SY; Nishida T; Ogawa W; Tobe K; Yamauchi T; Lim S;
    Lancet Diabetes Endocrinol; 2022 Mar; 10(3):193-206. PubMed ID: 35131037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.
    Wadden TA; Bailey TS; Billings LK; Davies M; Frias JP; Koroleva A; Lingvay I; O'Neil PM; Rubino DM; Skovgaard D; Wallenstein SOR; Garvey WT;
    JAMA; 2021 Apr; 325(14):1403-1413. PubMed ID: 33625476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis.
    Tan HC; Dampil OA; Marquez MM
    J ASEAN Fed Endocr Soc; 2022; 37(2):65-72. PubMed ID: 36578889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of subcutaneous semaglutide in adults with overweight or obese: a subgroup meta-analysis of randomized controlled trials.
    Zhang R; Hou QC; Li BH; Deng L; Yang YM; Li TX; Yao XQ; Yang LL; Lin XL; Liao YQ; Wang L; Liu YP; Tan J; Wan ZW; Shuai P
    Front Endocrinol (Lausanne); 2023; 14():1132004. PubMed ID: 37455913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial.
    Mu Y; Bao X; Eliaschewitz FG; Hansen MR; Kim BT; Koroleva A; Ma RCW; Yang T; Zu N; Liu M;
    Lancet Diabetes Endocrinol; 2024 Mar; 12(3):184-195. PubMed ID: 38330988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once-Weekly Semaglutide in Adolescents with Obesity.
    Weghuber D; Barrett T; Barrientos-Pérez M; Gies I; Hesse D; Jeppesen OK; Kelly AS; Mastrandrea LD; Sørrig R; Arslanian S;
    N Engl J Med; 2022 Dec; 387(24):2245-2257. PubMed ID: 36322838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.
    Davies M; Færch L; Jeppesen OK; Pakseresht A; Pedersen SD; Perreault L; Rosenstock J; Shimomura I; Viljoen A; Wadden TA; Lingvay I;
    Lancet; 2021 Mar; 397(10278):971-984. PubMed ID: 33667417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficacy and safety profile of once-weekly Semaglutide versus once-daily Sitagliptin as an add-on to metformin in patients with type 2 diabetes: a systematic review and meta-analysis.
    Patel T; Nageeta F; Sohail R; Butt TS; Ganesan S; Madhurita F; Ahmed M; Zafar M; Zafar W; Zaman MU; Varrassi G; Khatri M; Kumar S
    Ann Med; 2023; 55(2):2239830. PubMed ID: 37498865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.
    Wharton S; Calanna S; Davies M; Dicker D; Goldman B; Lingvay I; Mosenzon O; Rubino DM; Thomsen M; Wadden TA; Pedersen SD
    Diabetes Obes Metab; 2022 Jan; 24(1):94-105. PubMed ID: 34514682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical review of subcutaneous semaglutide for obesity.
    Phillips A; Clements JN
    J Clin Pharm Ther; 2022 Feb; 47(2):184-193. PubMed ID: 34964141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses.
    Kosiborod MN; Bhatta M; Davies M; Deanfield JE; Garvey WT; Khalid U; Kushner R; Rubino DM; Zeuthen N; Verma S
    Diabetes Obes Metab; 2023 Feb; 25(2):468-478. PubMed ID: 36200477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Gao X; Hua X; Wang X; Xu W; Zhang Y; Shi C; Gu M
    Front Pharmacol; 2022; 13():935823. PubMed ID: 36188627
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.